Gralise significantly improved patient’s mean pain scores compared with placebo in an 11-week clinical trial.
Rilpivirine, a diarylpyrimidine non-nucleoside reverse transcriptase inhibitor of HIV-1, approved for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve adult patients.
Ticagrelor significantly reduced the rate of cardiovascular death, MI or stroke compared with clopidogrel in a clinical trial.
Xarelto is indicated to prevent prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee- or hip-replacement surgery.
Fidaxomicin was noninferior to vancomycin among adults with Clostridium difficile-associated diarrhea in two randomized, double blind trials.
Daliresp is a selective phosphodiesterase 4 inhibitor that reduces risk for chronic obstructive pulmonary disease exacerbations in severely effected patients with COPD that have chronic bronchitis and a history of exacerbations.
Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation.
Makena is now available with indications to reduce risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Fortesta is a topical gel formulation of the androgen testosterone, indicated as replacement therapy in men for conditions associated with a deficiency or absence of the endogenous hormone.
Xerese is indicated for the early treatment of recurrent herpes labialis, to reduce the likelihood of ulcerative cold sores and to shorten the lesion-healing time in adults and adolescents.
Want to read more?
Please login or register first to view this content.
Next post in Drug Update